Eli Lilly and Company has entered a definitive agreement to acquire biotechnology company Prevail Therapeutics for a total consideration of up to $26.50 per share in cash or approximately $1.04bn.
The deal amount consists of $22.50 per share in cash or a total of $880m, which is payable at closing and one non-tradable contingent value right (CVR) worth up to $4.00 per share in cash or a total of around $160m.
Under the agreement, CVR has to be paid on getting first regulatory approval for commercial sale of a product from Prevail’s pipeline.
This approval can be from one of several countries such as the US, the UK, Japan, Germany, France, Italy or Spain.
The latest deal will establish a gene therapy programme at Lilly and be anchored by Prevail’s neuroscience asset portfolio.
Prevail has two gene therapies, PR001 and PR006, in the clinical development stage.
PR001 is being developed for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD) while PR006 is for frontotemporal dementia with GRN mutations (FTD-GRN).
In addition, Prevail’s preclinical pipeline includes PR004 and other potential gene therapies for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders.
Eli Lilly pain and neurodegeneration research vice president Mark Mintun said: “The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly, as we build a new gene therapy programme anchored by well-researched assets.”
The transaction is anticipated to close in the first quarter of next year.
Prevail Therapeutics founder and CEO Asa Abeliovich said: “In just over three years, Prevail has advanced two first-in-class gene therapy programmes into clinical development for PD-GBA, nGD, and FTD-GRN, established two manufacturing platforms, and developed a broad pipeline with great potential to impact patients in need of disease-modifying treatment options.”
In October, Lilly entered a definitive agreement to acquire biotech firm Disarm Therapeutics for an upfront payment of $135m.
by Pharmaceutical-Technology.com
Source: pharmaceutical-technology.com
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.
